These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 30249195)
41. Population-based screening for colorectal cancer using an immunochemical faecal occult blood test: a comparison of two invitation strategies. Van Roosbroeck S; Hoeck S; Van Hal G Cancer Epidemiol; 2012 Oct; 36(5):e317-24. PubMed ID: 22560885 [TBL] [Abstract][Full Text] [Related]
42. Screening for colon cancer: A test for occult blood. Khakimov N; Khasanova G; Ershova K; Gibadullina L; Vetkina T; Lobisheva G; Chumakova A Int J Risk Saf Med; 2015; 27 Suppl 1():S110-1. PubMed ID: 26639687 [TBL] [Abstract][Full Text] [Related]
43. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia. de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431 [TBL] [Abstract][Full Text] [Related]
45. Is a fecal occult blood test a useful tool for judging whether to perform capsule endoscopy in low-dose aspirin users with negative colonoscopy and esophagogastroduodenoscopy? Endo H; Kato T; Sakai E; Taniguchi L; Arimoto J; Kawamura H; Higurashi T; Ohkubo H; Nonaka T; Taguri M; Inamori M; Yamanaka T; Sakaguchi T; Hata Y; Nagase H; Nakajima A J Gastroenterol; 2017 Feb; 52(2):194-202. PubMed ID: 27095444 [TBL] [Abstract][Full Text] [Related]
46. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Haug U; Hundt S; Brenner H Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091 [TBL] [Abstract][Full Text] [Related]
47. Performance improvements of stool-based screening tests. van Dam L; Kuipers EJ; van Leerdam ME Best Pract Res Clin Gastroenterol; 2010 Aug; 24(4):479-92. PubMed ID: 20833351 [TBL] [Abstract][Full Text] [Related]
48. The ASAMET trial: a randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients. Petrera M; Paleari L; Clavarezza M; Puntoni M; Caviglia S; Briata IM; Oppezzi M; Mislej EM; Stabuc B; Gnant M; Bachleitner-Hofmann T; Roth W; Scherer D; Haefeli WE; Ulrich CM; DeCensi A BMC Cancer; 2018 Dec; 18(1):1210. PubMed ID: 30514262 [TBL] [Abstract][Full Text] [Related]
49. Colorectal cancer detection in an asymptomatic population: fecal immunochemical test for hemoglobin vs. fecal M2-type pyruvate kinase. Caviglia GP; Cabianca L; Fagoonee S; Gili FM Biochem Med (Zagreb); 2016; 26(1):114-20. PubMed ID: 26981025 [TBL] [Abstract][Full Text] [Related]
50. Diagnostic performance of guaiac-based fecal occult blood test in routine screening: state-wide analysis from Bavaria, Germany. Brenner H; Hoffmeister M; Birkner B; Stock C Am J Gastroenterol; 2014 Mar; 109(3):427-35. PubMed ID: 24343548 [TBL] [Abstract][Full Text] [Related]
51. Evaluation of a 5-Marker Blood Test for Colorectal Cancer Early Detection in a Colorectal Cancer Screening Setting. Werner S; Krause F; Rolny V; Strobl M; Morgenstern D; Datz C; Chen H; Brenner H Clin Cancer Res; 2016 Apr; 22(7):1725-33. PubMed ID: 26561557 [TBL] [Abstract][Full Text] [Related]
52. Test performance of faecal occult blood testing for the detection of bowel cancer in people with chronic kidney disease (DETECT) protocol. Wong G; Howard K; Chapman JR; Tong A; Bourke MJ; Hayen A; Macaskill P; Hope RL; Williams N; Kieu A; Allen R; Chadban S; Pollock C; Webster A; Roger SD; Craig JC BMC Public Health; 2011 Jun; 11():516. PubMed ID: 21714917 [TBL] [Abstract][Full Text] [Related]
53. DNA from fecal immunochemical test can replace stool for detection of colonic lesions using a microbiota-based model. Baxter NT; Koumpouras CC; Rogers MA; Ruffin MT; Schloss PD Microbiome; 2016 Nov; 4(1):59. PubMed ID: 27842559 [TBL] [Abstract][Full Text] [Related]
54. A Clinician's Guide to Fecal Occult Blood Testing for Colorectal Cancer. Bechtold ML; Ashraf I; Nguyen DL South Med J; 2016 Apr; 109(4):248-55. PubMed ID: 27043809 [TBL] [Abstract][Full Text] [Related]
55. [A double immunochemical method for detecting faecal haemoglobin and albumin in rectal screening]. Tarpay A; Szabadosné Németh M; Orosz E; Kásler M; Burai M; Pap A; Ottó S Magy Onkol; 2011 Nov; 55(4):268-73. PubMed ID: 22128309 [TBL] [Abstract][Full Text] [Related]
56. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection. Lohsiriwat V; Thavichaigarn P; Awapittaya B J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309 [TBL] [Abstract][Full Text] [Related]
57. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216 [TBL] [Abstract][Full Text] [Related]
58. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening. van Rossum LG; van Rijn AF; van Oijen MG; Fockens P; Laheij RJ; Verbeek AL; Jansen JB; Dekker E Int J Cancer; 2009 Aug; 125(4):746-50. PubMed ID: 19408302 [TBL] [Abstract][Full Text] [Related]
59. Immunochemical faecal occult blood tests in primary care and the risk of delay in the diagnosis of colorectal cancer. Högberg C; Karling P; Rutegård J; Lilja M; Ljung T Scand J Prim Health Care; 2013 Dec; 31(4):209-14. PubMed ID: 24191847 [TBL] [Abstract][Full Text] [Related]
60. Quantitation of faecal Wong SH; Kwong TNY; Chow TC; Luk AKC; Dai RZW; Nakatsu G; Lam TYT; Zhang L; Wu JCY; Chan FKL; Ng SSM; Wong MCS; Ng SC; Wu WKK; Yu J; Sung JJY Gut; 2017 Aug; 66(8):1441-1448. PubMed ID: 27797940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]